NASDAQ: $GLMD Brain metastasis (BM) remains one of the most formidable challenges in modern oncology. Despite the availability of surgical intervention, radiation, and immunotherapy, the prognosis for patients remains grim, with a 2-year survival rate currently standing below 10%. However, a new partnership between Galmed Pharmaceuticals and Tel Aviv University (TAU) aims to change this…